Ontology highlight
ABSTRACT:
SUBMITTER: Conseiller E
PROVIDER: S-EPMC508547 | biostudies-other | 1998 Jan
REPOSITORIES: biostudies-other
Conseiller E E Debussche L L Landais D D Venot C C Maratrat M M Sierra V V Tocque B B Bracco L L
The Journal of clinical investigation 19980101 1
The clinical potential of the p53 tumor suppressor gene is being evaluated currently for gene therapy of cancer. We have built a variant of wild-type p53, chimeric tumor suppressor 1 (CTS1), in which we have replaced the domains that mediate its inactivation. CTS1 presents some very interesting properties: (a) enhanced transcriptional activity; (b) resistance to the inactivation by oncogenic forms of p53; (c) resistance to the inactivation by MDM2; (d) lower sensitivity to E6-induced degradation ...[more]